From the Journals

Neoadjuvant/Adjuvant Doublet Significantly Improved Survival in Patients With Muscle-Invasive Bladder Cancer

The combination of the NECTIN4-directed antibody drug conjugate enfortumab vedotin-ejfv and the immunotherapy drug pembrolizumab is the established first-line standard-of-care treatment for patients w...

Share

Enfortumab vedotin, an antibody-drug conjugate, combined with pembrolizumab offers a promising first-line treatment for patients with locally advanced or metastatic urothelial carcinoma, as demonstrated in the KEYNOTE-B15/EV-304 study. This phase III trial enrolled 808 patients, showing significant improvements in event-free survival, overall survival, and pathologic complete response rates among those receiving this drug combination compared to standard gemcitabine and cisplatin. These findings were presented by Dr. Matthew D. Galsky at the ASCO Genitourinary Cancers Symposium.

Original Source(s)

Neoadjuvant/Adjuvant Doublet Significantly Improved Survival in Patients With Muscle-Invasive Bladder Cancer

  • by Jo Cavallo

  • March 18, 2026

Related Content

Timely Scans May Reduce Mortality in Patients Who Present to the ER With Hematuria

One in 10 patients who present to the emergency room (ER) with visible hematuria die within 3 months, new research from the United Kingdom has indicated. The WASHOUT study found that a scan administer...

New AACR President-Elect and Board Members Announced

The American Association for Cancer Research (AACR) has announced that Robert H. Vonderheide, MD, DPhil, has been named the 2026–2027 AACR President-elect. Dr. Vonderheide is an renowned cancer immuno...

Urine as a Cancer ‘Biopsy’?

Study traces tumor-derived extracellular vesicles from blood to urine through glomerular transport

  • March 18, 2026

  • 3 min